Trump Strikes Deal to Cut Weight-Loss Drug Prices. President Trump announced agreements with Eli Lilly and Novo Nordisk to reduce prices of popular weight-loss drugs. Consumers will pay between $245 and $350 per month for obesity treatments like Wegovy and Zepbound. The deals expand access through Medicare and Medicaid, with Eli Lilly receiving a three-year tariff exemption. About 10% of Medicare beneficiaries will qualify for GLP-1 drugs at a monthly cost of $50. A new government-run website, TrumpRx, will sell discounted drugs starting in January. Eli Lilly’s orforglipron pill will cost $149 for the lowest dose, while Zepbound injections start at $299. Medicare is barred from covering weight-loss drugs, but some coverage exists for diabetes or heart disease treatment. Pfizer, AstraZeneca, and EMD Serono have also reached price-cutting agreements with the administration. Instructions: THIS VIDEO MUST NOT BE EDITED FOR LENGTH TO COMBINE WITH OTHER CONTENT